Deerfield Management

Founded 1994


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 66
Average round size
The average size of a deal this fund participated in
Portfolio companies 57
Rounds per year 2.44
Lead investments 9
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 18
Key employees Soon

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Therapeutics
  • Pharmaceutical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Deerfield Management:
There are no funds here. If we find new data, we will add it here.
Typical Co-investors
Deerfield Management is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Deerfield Management:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

ARS Pharmaceuticals

Health Care
$55M31 Aug 2021 San Diego, California, United States


Clinical Trials
$112M05 Aug 2021 Oxford, England, United Kingdom


Artificial Intelligence
Health Care
Health Diagnostics
Machine Learning
Predictive Analytics
$350M23 Jul 2021 Stamford, Connecticut, United States


Health Care
$53M28 Jun 2021 New York, New York, United States


Health Care
Health Diagnostics
$60M23 Jun 2021 Toronto, Ontario, Canada

Insilico Medicine

Artificial Intelligence
Health Care
$255M22 Jun 2021 Hong Kong Island, Hong Kong, China


$107M10 Jun 2021 California, United States

Larimar Therapeutics

$95M21 May 2021 Lower Merion Township, Pennsylvania, United States

Cohere Health

Consumer Software
Health Care
$36M13 Apr 2021 Boston, Massachusetts, United States
HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

ARS Pharmaceuticals Raises $55M in Series D Funding

– ARS Pharmaceuticals, a San Diego CA-based pharmaceutical company, raised $55M in Series D funding.
– The round was led by SR One with participation from RA Capital Management and Deerfield Management.
– The company intends to use the funds to advance Neffy through approval, to support initial launch activities, and to evaluate it in clinical studies for additional indications.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Deerfield Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: